New reporting date, Vitrolife's interim report and

New reporting date, Vitrolife's interim report and invitation to conference call
on the interim report

Due to the merger between Vitrolife's largest shareholder, Skanditek, and Bure,
Vitrolife will change reporting date for the interim report January-September to
Monday    October 26, 2009.
Invitation to attend Vitrolife's conference call regarding presentation of the
interim report for the period January-September 2009. The presentation will be
held in English.


Time: Tuesday, October 27, 2009 at 10 a.m. CET.
Registration can be done in advance under the following link:
https://eventreg1.conferencing.com/webportal3/reg.html?Acc=830257&Conf=169038 
or shortly before time of the conference starts on:
Telephone number: +46 8 505 201 10 (Please quote 848837)
Conference name: Vitrolife

Vitrolife participants:
Magnus Nilsson, CEO
Eva Nilsagård, CFO

The press release for Vitrolife's interim report will be released at 3.00 p.m.
CET on October 26. 

Before the conference call, slides will be available at the company web page,
www.vitrolife.com, under the section Investors/News.
A recorded version of the presentation will be available for seven days on
number                    +46 8 505 203 33, access code 848837.

Gothenburg 
October 19,2009

Magnus Nilsson
CEO

Queries should be addressed to: 
Eva Nilsagård, CFO, phone +46 31 721 80 13

________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 160 employees and the company's products
are sold in more than 85 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France, Italy and Japan.
Production facilities are located in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
________________________________________________________________________________
_________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on Monday
October 19, 2009 at 09:00 am CET.

This is a translation of the Swedish version of the notice. When in doubt, the
Swedish wording prevails.
New reporting date, Vitrolife's interim report and invitation to conference call on the interim report

Attachments
